Prostat Kanserinde Biyobelirteçler

Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17:159-63, 1979

Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29- 38.

Link, Richard E., et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2,304 patients undergoing prostate cancer screening. The Journal of urology, 2004, 171.6 Part 1: 2234-2238.. doi: 10.1097/01.ju.0000127736.86597.e7.

MOTTET, Nicolas, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. European urology, 2021, 79.2: 243-262. doi.org/10.1016/j.eururo.2020.09.042

Partin AW, Criley SR, Subong EN, et al. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol. 1996 Apr;155(4):1336-9. doi.org/10.1016/S0022-5347(01)66260-8

Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283-90. doi: 10.1016/s0022-5347(17)35233-3.

Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9. doi: 10.1016/s0022-5347(17)49698-4.

Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997 May 14;277(18):1452-5. 10.1001/jama.1997.03540420048028.

Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995 Aug;154(2 Pt 1):407-13. doi: 10.1097/00005392-199508000-00023.

Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology. 1989 Jun;33(6):465. doi: 10.1016/0090-4295(89)90131-3.

Kawakami J, Siemens DR, Nickel JC. Prostatitis and prostate cancer: implications for prostate cancer screening. Urology. 2004 Dec;64(6):1075-80. doi: 10.1016/j.urology.2004.07.017.

Tarhan F, Orçun A, Küçükercan I, et al. Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology. 2005 Dec;66(6):1234-8. doi: 10.1016/j.urology.2005.06.077.

Oesterling JE, Rice DC, Glenski WJ, et al. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993 Sep;42(3):276-82. doi: 10.1016/0090-4295(93)90616-i.

Crawford ED, Mackenzie SH, Safford HR, et al. The effect of bicycle riding on serum prostate specific antigen levels. J Urol. 1996 Jul;156(1):103-5. doi: 10.1016/s0022-5347(01)65954-8.

Tchetgen MB, Song JT, Strawderman M, et al. Ejaculation increases the serum prostate-specific antigen concentration. Urology. 1996 Apr;47(4):511-6. doi: 10.1016/S0090-4295(99)80486-5.

Parker ME. Free PSA for Detecting Prostate Cancer. JAMA. 1998;280(21):1825. doi:10.1001/jama.280.21.1825

Catalona WJ, Bartsch G, Rittenhouse HG,et al. SD. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004 Jun;171(6 Pt 1):2239-44. doi: 10.1097/01.ju.0000127737.94221.3e.

Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun;71(6):1016-9. doi: 10.1016/j.urology.2007.12.008. Epub 2008 Mar 21.

Günay LM, Yazıcı S, Özen H. PSA nerden geldi nereye gidiyor? Bull Urooncol 2011;10(2):5-10

Catalona WJ, Southwick PC, Slawin KM, et al . Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 2000, 56.2: 255-260. doi.org/10.1016/S0090-4295(00)00637-3.

Bjartell A, Montironi R, Berney DM, et al. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol. 2011 Jun;50 Suppl 1:76-84. doi: 10.3109/0284186X.2010.531284.

Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007 May;38(5):696-701. doi: 10.1016/j.humpath.2006.11.012. Epub 2007 Feb 22.

Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999 Dec 1;59(23):5975-9. PMID: 10606244.

Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003 Nov;62(5 Suppl 1):34-43. doi: 10.1016/s0090-4295(03)00759-3.

Horasanlı K, Aydın M. Tekrarlayan prostat muayenelerinde ideal bir çalışma şeması var mı? PCA3 PSA kadar yararlı etkileri? Bull Urooncol 2010;9:47-52.

Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

Nicholson A, Mahon J, Boland A, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191. doi: 10.3310/hta19870.

Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

Lendínez-Cano G, Ojeda-Claro AV, Gómez-Gómez E, et al. Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test. Prostate. 2021 Sep;81(12):857-865. doi: 10.1002/pros.24182. Epub 2021 Jun 29.

Tomlins SA, Rhodes DR, Perner S, et al. Transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679.

Tomlins SA, Day JR, Lonigro RJ,et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267(27):19027-30.

Wikstrom P, Lissbrant IF, Stattin P, et al. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51(4):268-75. doi.org/10.1002/pros.10083

Jakoby WB. The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol. 1978;46:383-414. doi: 10.1002/9780470122914.ch6.

Lee WH, Morton RA, Epstein JI,et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7. doi: 10.1073/pnas.91.24.11733.

Harden SV, Guo Z, Epstein JI, et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003 Mar;169(3):1138-42. doi: 10.1097/01.ju.0000049627.90307.4d.

Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001 Apr;22(2):184-204. doi: 10.1210/edrv.22.2.0424.

Shariat SF, Semjonow A, Lilja H, et al. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011 Jun;50 Suppl 1(Suppl 1):61-75. doi: 10.3109/0284186X.2010.542174.

Nam RK, Diamandis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol. 2000 Mar;18(5):1036-42. doi: 10.1200/JCO.2000.18.5.1036.

Becker C, Piironen T, Pettersson K, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol. 2000 Jan;163(1):311-6.

Becker C, Piironen T, Pettersson K, et al. Clinical value of human glandular kallikrein 2 and free and total prostatespecific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 2000;55(5):694-9. doi.org/10.1016/S0090-4295(99)00585-3.

Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008;6:19. doi.org/10.1186/1741-7015-6-19

Luo J, Zha S, Gage WR, et al. Alpha-methylacylCoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220-6.

Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287(13):1662-70. doi:10.1001/jama.287.13.1662.